Heart Disease (Cardiovascular Disease)

1. Defining the Core Concept

Heart disease is an umbrella term for a range of conditions that affect the structure and function of the heart. It is often used interchangeably with cardiovascular disease (CVD), though CVD is a broader term that includes both heart and blood vessel conditions such as stroke. Common types of CVD include coronary heart disease (CHD), stroke, hypertension (high blood pressure), congestive heart failure, atrial and ventricular arrhythmias, congenital cardiovascular disorders, rheumatic heart disease, peripheral artery disease, and deep vein thrombosis. Among these, coronary heart disease—also known as ischemic heart disease (IHD)—is the most common and a leading cause of deaths worldwide. CHD occurs when the coronary arteries, which supply oxygen‑rich blood to the heart muscle, become narrowed or blocked due to atherosclerosis—the gradual buildup of fatty deposits (plaque) on the inner arterial walls. Reduced blood flow leads to ischemia (oxygen deprivation), which can cause chest pain (angina) or, if a vessel becomes completely obstructed, a myocardial infarction (heart attack). This article focuses primarily on coronary heart disease, its mechanisms, epidemiology, and clinical features.

2. Pathophysiology of Ischemic Heart Disease

The primary underlying cause of ischemic heart disease is atherosclerosis. Atherosclerosis is a progressive, inflammatory disease of the arterial wall. It begins with damage to the endothelium (the inner lining of the artery) caused by risk factors such as high blood pressure, smoke, high LDL cholesterol, diabetes, and chronic inflammation. Damaged endothelium allows LDL cholesterol particles to infiltrate the vessel wall, where they become oxidized and trigger an inflammatory response. Macrophages engulf the oxidized LDL, forming foam cells that accumulate as fatty streaks. Over time, these streaks evolve into larger plaques composed of a lipid‑rich core covered by a fibrous cap. As plaques enlarge, they narrow the arterial lumen, reducing blood flow. The most dangerous event is plaque rupture—when the fibrous cap tears, exposing the thrombogenic core to the bloodstream. This triggers platelet aggregation and clot formation (thrombosis), which can abruptly occlude the artery, causing acute myocardial infarction. Atherosclerosis does not occur in isolation; it typically affects multiple arterial beds, which is why patients with CHD are also at increased risk for stroke and peripheral artery disease.

3. Clinical Forms of Coronary Heart Disease

CHD manifests in two primary clinical forms: stable angina and acute coronary syndrome (which includes unstable angina and myocardial infarction).

Stable angina is chest pain or discomfort that occurs predictably during physical exertion or emotional stress and resolves with rest or nitroglycerin. It reflects a fixed, stable atherosclerotic narrowing that limits blood flow during periods of increased myocardial oxygen demand. Patients typically describe pressure, squeezing, or tightness in the chest, sometimes radiating to the left arm, jaw, or back.

Acute coronary syndrome (ACS) represents an acute reduction in blood flow, usually due to plaque rupture and thrombosis. Unstable angina is chest pain that occurs at rest, lasts longer than 20 minutes, or becomes more frequent and severe; it is a medical emergency because it often presages a heart attack. Myocardial infarction (heart attack) occurs when prolonged ischemia causes irreversible damage to heart muscle. There are two types: STEMI (ST‑elevation myocardial infarction), caused by a complete blockage of a major coronary artery, leading to a long interruption of blood supply and extensive muscle damage, and NSTEMI (non‑ST‑elevation myocardial infarction), characterized by a partially blocked artery or temporary occlusion, resulting in less extensive damage. Symptoms of MI include chest pain, shortness of breath, nausea, diaphoresis (cold sweat), and lightheadedness. Prompt reperfusion (via percutaneous coronary intervention or thrombolytics) is essential to salvage myocardium and improve survival.

4. Epidemiology and Burden

Heart disease is the leading cause of deaths globally and in most industrialized nations. In the United States, an estimated 16.3 million Americans aged 20 and older have CHD, representing a prevalence of 7%. Prevalence is higher in men (8.3%) than in women (6.1%). Among racial and ethnic groups, non‑Hispanic white men have the highest prevalence (8.5%), followed by non‑Hispanic black men (7.9%) and Mexican American men (6.3%). For women, non‑Hispanic black women have the highest rate (7.6%). An estimated 7.9 million Americans have suffered a heart attack, and 9 million have experienced angina pectoris. The overall prevalence of myocardial infarction in adults aged 20 and older is 3.1%, with men having higher rates than women. In the United Kingdom, CHD is responsible for approximately 66,000 deaths annually, and 2.3 million people are living with CHD. Globally, WHO data indicate that ischemic heart disease and stroke are the most common forms of CVD, with IHD typically resulting from atherosclerosis. Hypertension is a major risk factor for cardiovascular disease. The WHO Global Hypertension Report 2025 states that 1.4 billion people worldwide live with hypertension, yet only one in five have it under control. In 99 countries, control rates remain below 20%. Scaling up effective treatment for just 50% of affected individuals could prevent 76 million deaths by 2050 and save USD 100 billion annually in healthcare costs. In Australia, an estimated 600,000 adults (3.0% of the adults population) have CHD at some time in their lives. In 2023, there were an estimated 57,100 acute coronary events—approximately 156 events every day. CHD was the underlying cause of 18,600 deaths (9.8% of all deaths) in 2022.

5. Risk Factors for Heart Disease

Risk factors for CHD are categorized as modifiable (those that can be changed through lifestyle or medication) and non‑modifiable (age, family history, and genetics). Major modifiable risk factors include:

• Hypertension: High blood pressure damages arterial endothelium and accelerates atherosclerosis.
• Dyslipidemia: Elevated LDL cholesterol and low HDL cholesterol promote plaque formation.
• Diabetes mellitus: Hyperglycemia increases oxidative stress, inflammation, and endothelial dysfunction.
• Obesity and physical inactivity: These contribute to hypertension, dyslipidemia, and diabetes.
• Unhealthy diet: Diets high in saturated fats, trans fats, sodium, and refined carbohydrates increase risk.
• Psychological stress: Chronic stress may increase blood pressure and promote inflammation

6. Diagnostic Tools

Several tests are used to diagnose CHD and assess its severity:

• Electrocardiogram (ECG/ EKG): Records the heart‘s electrical activity. During a heart attack, characteristic ST‑segment elevation or depression may be seen. Resting ECG may be normal in stable angina.
• Exercise stress test: Monitors ECG and blood pressure while the patient exercises on a treadmill or bicycle. ST‑segment changes, chest pain, or arrhythmias during exercise suggest significant coronary stenosis.
• Echocardiogram: Uses ultrasound to visualize heart structures, assess chamber sizes, valve function, and regional wall motion abnormalities indicative of prior or ongoing ischemia.
• Coronary angiography (cardiac catheterization): The gold standard for diagnosing coronary artery disease. A contrast agent is injected into the coronary arteries via a catheter inserted through the femoral or radial artery. X‑ray imaging reveals the location and severity of stenoses.
• Cardiac computed tomography (CT) angiography: A non‑invasive alternative to invasive angiography, using CT imaging to visualize the coronary arteries and quantify coronary artery calcium (CAC score).
• Cardiac biomarkers: Troponin I or T are highly sensitive and specific markers of myocardial injury. Elevated troponin indicates myocardial infarction. Creatine kinase‑MB (CK‑MB) is another biomarker, though less specific than troponin.

7. Presenting the Full Picture: Prevention and Management

CHD is largely preventable through modification of risk factors. Population‑based strategies include tobaccos control legislation, food labeling, salt reduction initiatives, and promotion of physical activity. Individual prevention focuses on lifestyle modification: smoke cessation, adoption of a Mediterranean‑style diet (rich in fruits, vegetables, whole grains, lean proteins, and unsaturated fats), regular aerobic exercise (at least 150 minutes per week of moderate‑intensity activity), weight management, and stress reduction. Pharmacological management includes antiplatelet agents (aspirin), lipid‑lowering drug (statins, ezetimibe, PCSK9 inhibitors), antihypertensive medications (ACE inhibitors, beta‑blockers, calcium channel blockers), and antidiabetic medications. Invasive treatment options for established CHD include percutaneous coronary intervention (stenting) and coronary artery bypass grafting (CABG). Despite significant advances, CHD remains a leading cause of premature deaths and disability. The decline in age‑standardized mortality rates observed in many high‑income countries over the past several decades reflects improvements in prevention, acute care, and rehabilitation, but the absolute burden remains substantial due to population aging and rising prevalence of obesity and diabetes.

8. Question-and-Answer Section

Q1: What is the difference between a heart attack and cardiac arrest?
A: A heart attack (myocardial infarction) occurs when blood flow to a part of the heart muscle is blocked, causing tissue damage. Cardiac arrest is an electrical malfunction of the heart that causes it to stop beating effectively, leading to loss of consciousness and cessation of breathing. A heart attack can trigger cardiac arrest, but the two are distinct conditions. Cardiac arrest requires immediate defibrillation; heart attack requires reperfusion (stent or thrombolytics).

Q2: Can heart disease be reversed?
A: While established atherosclerotic plaques cannot be fully reversed, intensive lifestyle changes (especially a low‑fat, plant‑based diet) combined with aggressive lipid‑lowering therapy (high‑intensity statins, PCSK9 inhibitors) can reduce plaque volume and stabilize plaques, preventing rupture and future events. Coronary artery calcium (CAC) does not regress, but the risk of future events can be substantially reduced. Progression to heart failure or arrhythmias can be slowed or prevented with appropriate treatment.

Q3: What is a normal blood pressure?
A: According to the American College of Cardiology/American Heart Association, normal blood pressure is less than 120/80 mmHg. Elevated blood pressure is 120‑129/<80 mmHg. Stage 1 hypertension is 130‑139/80‑89 mmHg. Stage 2 hypertension is ≥140/90 mmHg. Hypertensive crisis (>180/>120 mmHg) requires emergency treatment. Achieving blood pressure control (typically <130/80 mmHg for most adults, lower for high‑risk groups) is a primary goal for preventing heart disease, stroke, and kidney disease.

Q4: How is angina different from a heart attack?
A: Angina is chest discomfort caused by reversible myocardial ischemia without permanent damage. It typically occurs with exertion or stress and resolves with rest or nitroglycerin. A heart attack (myocardial infarction) is caused by irreversible ischemia due to prolonged blockage, leading to muscle necrosis. Heart attack symptoms are often more severe and prolonged (>20 minutes) and may not resolve with rest. Both require medical evaluation, but a heart attack is a medical emergency requiring immediate reperfusion.

Q5: What is atherosclerosis?
A: Atherosclerosis is the gradual buildup of fatty plaques within the arterial walls. It begins with endothelial injury, followed by infiltration of LDL cholesterol, inflammatory cell recruitment, and formation of a lipid‑rich plaque. Plaques can narrow arteries, reducing blood flow, or rupture, causing thrombosis that completely blocks the artery. Atherosclerosis is the underlying cause of most heart attacks, strokes, and peripheral artery disease. Risk factors include hypertension, smoke, high LDL, diabetes, obesity, and sedentary lifestyle.

Q6: At what age should cardiovascular risk assessment begin?
A: The American Heart Association recommends that all adults aged 20 years and older have their blood pressure, body mass index, waist circumference, and pulse checked at routine healthcare visits. Lipid panels (total cholesterol, LDL, HDL, triglycerides) should be measured every 4‑6 years in adults aged 20‑39 years with no risk factors, and more frequently (every 1‑2 years) in those aged 40‑75 years or with risk factors. A global risk score (e.g., ASCVD risk estimator) can help guide prevention strategies.

https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/all-heart-stroke-and-vascular-disease/coronary-heart-disease
https://www.ncbi.nlm.nih.gov/sites/books/NBK83160/
https://www.who.int/health-topics/cardiovascular-diseases
https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease
https://www.nhlbi.nih.gov/health/coronary-heart-disease
https://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/symptoms-causes/syc-20350613
https://www.acc.org/latest-in-cardiology/articles/2018/01/22/18/23/2017-hypertension-clinical-practice-guidelines
https://www.ncbi.nlm.nih.gov/books/NBK470402/